Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EORTC CLTF 2021 | Updates on the brentuximab vedotin for CTCL

Chalid Assaf • 14 Oct 2021
EORTC CLTF 2021
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases Brentuximab vedotin

Chalid Assaf, MD, PhD, Helios Klinikum Krefeld, Krefeld, Germany, discusses the latest updates in the treatment of cutaneous T-cell lymphoma (CTCL), in particular highlighting the use of brentuximab vedotin in patients with late-stage disease, and questioning the importance of CD30 positivity in its use. Dr Assaf reports that CTCL tumor samples expressing below 10% of CD30 were found to have very good responses to brentuximab vedotin. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

More from Chalid Assaf

3:21
Low-dose gemcitabine for advanced CTCL
Chalid Assaf • 14 Oct 2021
2:46
ALCANZA: brentuximab vedotin for CTCL
Chalid Assaf • 14 Oct 2021
1:26
Chlormethine gel for mycosis fungoides
Chalid Assaf • 14 Oct 2021
1:15
Improving TTD and supporting patient advocacy in CTCL
Chalid Assaf • 14 Oct 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals